📈 Live Market Tracking
Every NSE and BSE corporate filing, read and explained by AI within minutes — impact, key figures, short/long-term view and what to watch.
Live · AI analyzer runs every 5 min (07:00–23:55 IST)
Latest filing: 2026-10-09 20:21
351 analysed today
FollowTelegram
351
Today
149,752
All-time analysed
42,937
Positive
6,664
Negative
91,466
Neutral
8,617
Watch
📊 Last 7 days — analysed filings by sentiment
Note: These are AI-generated, educational summaries of public NSE
filings — grounded in each document, but not investment advice and possibly incomplete.
Verify against the original filing and consult a SEBI-registered adviser before acting.
33 announcements match the current filters (relevance ≥ 5).
Cohance Lifesciences Appoints Former Intas Exec Abhimanyu Ojha as CFO Effective Oct 12, 2026
Cohance Lifesciences has appointed Mr. Abhimanyu Ojha as its Chief Financial Officer and Key Managerial Personnel, effective October 12, 2026. Mr. Ojha brings over two decades of pharma finance experience, previously serving as Global CFO & President Finance at Intas Pharmaceuticals, with earlier stints at Viatris, Sun Pharma, and Ranbaxy. The appointment comes as the company navigates integration following its Casper Pharma merger, aiming to turnaround performance after reporting a net loss of Rs 45.19 crore in Q1 FY27 (ended June 2026). Mr. Ojha is also designated as an authorized KMP for materiality disclosures alongside CEO Umang Vohra.
Confidence: HIGH
What changedMr. Abhimanyu Ojha takes over as Chief Financial Officer and Key Managerial Personnel effective October 12, 2026.
Why it mattersA seasoned CFO from top-tier pharma players (Intas, Sun Pharma) strengthens financial leadership during post-merger integration and margin recovery efforts.
Effective appointment date: 12 October 2026Professional experience: over two decadesCompany TTM revenue context: Rs 2141 CrCompany market cap context: Rs 9236 Cr
📅 Short termNeutral to mildly positive sentiment as executive leadership stabilizes without business interruption.
📈 Long termBrings strong M&A, treasury, and global compliance leadership critical for scaling the combined CDMO entity toward its targeted 20-25% growth path.
⚠ Risk flags
- Operational turnaround risk following recent Q1 net loss of Rs 45.19 Cr
- Integration execution across acquired entities
Key Highlights
Appointment of Mr. Abhimanyu Ojha as CFO and KMP effective October 12, 2026
Candidate brings over 20 years of experience across Intas Pharmaceuticals, Viatris, Sun Pharma, and Ranbaxy
Board approved the appointment at its meeting held on October 9, 2026 (concluded in 15 minutes: 7:45 pm to 8:00 pm)
Authorized as KMP for SEBI Regulation 30(5) materiality disclosures alongside Chairman & Group CEO Umang Vohra
👀 What to Watch
Track the upcoming Q2 FY27 earnings commentary to gauge the new CFO's financial strategy, cost-rationalization measures, and integration roadmap following the recent margin pressures.
USFDA Concludes Inspection at Jaggaiahpet API Facility with 5 Form 483 Observations
Cohance Lifesciences completed a USFDA inspection at its Jaggaiahpet API manufacturing facility in Andhra Pradesh, conducted between 14 September and 19 September 2026. The audit ended with the issuance of Form FDA 483 containing 5 observations. The company stated that it has initiated Corrective and Preventive Actions (CAPA) and will reply within the mandated timeline. Given past regulatory challenges such as an Official Action Indicated (OAI) status at its Nacharam formulations plant, resolution of these observations remains key for export continuity.
Confidence: HIGH
What changedUSFDA concluded an on-site inspection at Cohance's Jaggaiahpet API facility and issued 5 observations under Form FDA 483.
Why it mattersUSFDA compliance is vital for Cohance's API business and export pipeline, particularly as the firm targets 10 DMF filings and works past previous regulatory halts.
Form 483 observations: 5Audit end date: 19 September 2026FEI Number: 3005554260
📅 Short termLikely to create short-term overhang on the stock until the severity (procedural vs. data integrity/repeat) of the 5 observations is clarified.
📈 Long termIf resolved satisfactorily (Voluntary Action Indicated), commercial supply and DMF filings remain unaffected; an escalation to Warning Letter or OAI would impair US CDMO/API expansion.
⚠ Risk flags
- Potential escalation to Official Action Indicated (OAI) or Warning Letter if CAPA response is deemed inadequate
- Risk of delayed product approvals or DMF clearances for US exports
Key Highlights
USFDA audit conducted from 14 September to 19 September 2026 at Jaggaiahpet API site
Inspection concluded with 5 Form FDA 483 observations issued
FEI number of the facility: 3005554260
Company is initiating CAPA and preparing response within the stipulated deadline
👀 What to Watch
Track the nature and severity of the 5 observations once made public, and monitor the USFDA's final classification (VAI vs. OAI) following the company's CAPA response.
Cohance Lifesciences Infuses $10 Million in US Subsidiary NJ Bio via CCPS
Cohance Lifesciences has remitted $10 million (~Rs 83-85 cr) towards the subscription of 188,680 Compulsorily Convertible Preferred Stock (CCPS) of its US subsidiary, NJ Bio Inc., at $53.00 per share. The CCPS are convertible into equity shares after 3 years, funded via internal accruals. NJ Bio is an Antibody Drug Conjugate (ADC) focused CRDMO whose turnover stood at USD 23.5 million in CY2025 (down from USD 32.6 million in CY2024). The investment supports NJ Bio's capex and growth initiatives, aligning with Cohance's strategy to scale high-margin ADC capabilities.
Confidence: HIGH
What changedCohance remitted $10 million in cash to subscribe to 188,680 CCPS of its US subsidiary NJ Bio, completing the board approval originally granted in December 2025.
Why it mattersProvides dedicated growth capital and capex funding to NJ Bio to strengthen Cohance's presence in high-margin, specialized ADC and conjugation technologies.
Investment Amount: USD 10 millionNumber of CCPS: 188,680Price per CCPS: USD 53.00NJ Bio CY2025 Turnover: USD 23.5 millionNJ Bio CY2024 Turnover: USD 32.6 million
📅 Short termNeutral to mildly positive; transaction closure expected by end of September 2026 with no immediate impact on reported consolidated revenues.
📈 Long termSupports the expansion of specialized ADC/bioconjugation capabilities, which Cohance targets to account for low-20s percentage of CDMO revenue over time.
⚠ Risk flags
- NJ Bio revenue contracted by ~28% in CY2025 ($23.5M vs $32.6M in CY2024)
- Related-party capital allocation
Key Highlights
Remitted aggregate consideration of USD 10 million via internal accruals
Subscribing to 188,680 CCPS of NJ Bio at USD 53.00 per share
CCPS are convertible into equity shares of NJ Bio after 3 years
Target entity NJ Bio posted CY2025 revenue of USD 23.5 million vs USD 32.6 million in CY2024
Transaction expected to fully close before the end of September 2026
👀 What to Watch
Track the completion of the CCPS issuance by end-September 2026 and monitor whether NJ Bio's revenue rebounds to drive CDMO segment margin expansion in upcoming quarters.
USFDA Concludes Shamshabad Plant Inspection with 4 Form 483 Observations
Cohance Lifesciences completed a USFDA inspection of its finished dosage formulation (FDF) facility in Shamshabad, Telangana, conducted between 27 August and 4 September 2026. The inspection concluded with the issuance of a Form FDA 483 containing 4 observations. The company confirmed it has initiated Corrective and Preventive Actions (CAPA) and plans to submit its response within the stipulated regulatory timeline. This follows prior regulatory scrutiny across its manufacturing network, making the final classification critical.
Confidence: HIGH
What changedUSFDA completed its audit at the Shamshabad FDF facility, issuing a Form 483 with 4 procedural/compliance observations.
Why it mattersFormulation plants driving US supplies require clearance to avoid import alerts, Warning Letters, or delays in new product approvals/DMF filings.
Form 483 observations: 4Inspection dates: 27 August to 4 September 2026TTM revenue context: Rs 2072 Cr
📅 Short termMarket sentiment may remain cautious until the severity of the 4 observations is clarified through the final EIR or USFDA response review.
📈 Long termIf resolved smoothly with a VAI (Voluntary Action Indicated) status, standard commercialization pipelines will continue without structural disruptions.
⚠ Risk flags
- Risk of adverse USFDA classification (OAI/Warning Letter) if CAPA is deemed inadequate
- Potential delays to pending US formulations and product launches
Key Highlights
USFDA conducted inspection from 27 August to 4 September 2026
Formulation (FDF) plant at Shamshabad, Telangana received Form FDA 483 with 4 observations
CAPA initiated by the company to respond within the stipulated USFDA timeline
Formulation compliance remains key for export revenue (export exposure ~85%)
👀 What to Watch
Track the submission of the CAPA response (typically 15 business days) and the subsequent final inspection classification (NAI/VAI vs OAI) or Establishment Inspection Report (EIR) from the USFDA.
Cohance to invest USD 18M to boost ADC business via NJ Bio and Aruka Bio acquisitions
Cohance Lifesciences has announced two transactions totaling USD 18 million funded entirely via internal accruals to strengthen its Antibody-drug Conjugate (ADC) capabilities. The company is investing USD 13 million to raise its stake in NJ Bio from 56.0% to 67.3%, acquiring shares from minority holders while founder Dr. Naresh Jain retains 32.7%. Additionally, Cohance is investing USD 5 million to acquire a controlling 65% direct stake in preclinical biotech Aruka Bio (with NJ Bio holding 25% and Dr. Jain holding 10%). The transactions are slated to close by the end of September 2026.
Confidence: HIGH
What changedCohance increased its controlling stake in NJ Bio to 67.3% and acquired direct control (65%) of proprietary ADC platform Aruka Bio.
Why it mattersEnhances end-to-end CRDMO capabilities in high-margin, high-growth niche segments (ADCs) and adds proprietary preclinical assets for future out-licensing and co-development.
Total ADC investment: USD 18 millionNJ Bio investment: USD 13 millionNJ Bio stake increase: 56.0% to 67.3%Aruka Bio direct stake: 65%Target closing date: end of September 2026
📅 Short termPositive sentiment driver as management strengthens its specialty CDMO positioning without taking on external debt.
📈 Long termAligns with Cohance's target to increase niche technologies (ADCs and Oligos) to low-20s percentage of CDMO revenue, broadening higher-margin CRDMO offerings.
⚠ Risk flags
- Aruka Bio lead program is preclinical, carrying inherent clinical development and partnering risks
- Subject to customary closing conditions and definitive agreements by September 2026
Key Highlights
Total capital outlay of USD 18 million funded entirely through internal accruals
Increases equity stake in NJ Bio from 56.0% to 67.3% via a USD 13 million investment
Acquires a 65% controlling stake in preclinical ADC biotech Aruka Bio for USD 5 million
Target completion date set for end of September 2026, subject to definitive agreements and closing conditions
👀 What to Watch
Track the completion of definitive agreements by the end of September 2026 and monitor integration timelines for customer contract wins in the ADC/bioconjugation vertical.
Cohance Lifesciences Invests $18 Million to Expand ADC Holdings via NJ Bio and Aruka Bio
Cohance Lifesciences has approved an aggregate investment of USD 18 million (~Rs 150 cr) via internal accruals to consolidate its Antibody-Drug Conjugate (ADC) operations. The company will invest USD 13 million to raise its stake in NJ Bio from 56.0% to 67.3% by purchasing 244,587 shares at USD 53.00 per share. Additionally, it will invest USD 5 million to acquire a controlling 65% direct equity stake (57.8% fully diluted) in preclinical-stage platform Aruka Bio. Both transactions are targeted for completion by the end of September 2026.
Confidence: HIGH
What changedCohance is increasing its majority ownership in subsidiary NJ Bio to 67.3% and buying a controlling 65% stake in step-down associate Aruka Bio.
Why it mattersThe reorganisation consolidates Cohance's high-margin Antibody-Drug Conjugate (ADC) capabilities and gives dedicated leadership to Aruka Bio's proprietary preclinical ADC drug pipeline.
Total deal value: USD 18 millionNJ Bio stake post-deal: 67.3%NJ Bio acquisition price per share: USD 53.00Aruka Bio direct ownership: 65%NJ Bio CY2025 turnover: USD 23.5 millionDeal value vs TTM revenue: ~7.2%
📅 Short termDeal closing by late September 2026 will lead to full consolidation of Aruka Bio and increased profit share from NJ Bio.
📈 Long termStrengthens Cohance's end-to-end CRDMO bioconjugation capabilities and opens upside potential from Aruka Bio's proprietary ADC development partnerships.
⚠ Risk flags
- Aruka Bio is pre-revenue (preclinical stage) requiring continuous R&D and partner traction
- NJ Bio CY2025 revenue declined to USD 23.5 million from USD 32.6 million in CY2024
Key Highlights
Investing USD 13 million (~Rs 108 cr) to increase stake in NJ Bio from 56.0% to 67.3% at USD 53.00 per share
Investing USD 5 million (~Rs 42 cr) to acquire a 65% direct stake in Aruka Bio, Inc.
Total investment of USD 18 million funded entirely through internal accruals
NJ Bio reported turnover of USD 23.5 million in CY2025 (vs USD 32.6 million in CY2024)
Target completion date for both acquisitions is set for end of September 2026
👀 What to Watch
Track the formal execution and closing of definitive agreements by late September 2026, along with integration benefits and contract wins in the ADC CDMO business in upcoming quarterly results.
CRISIL withdraws ratings on Rs 72.5 Cr facilities after 'Issuer Not Cooperating' migration
Cohance Lifesciences has requested the withdrawal of CRISIL ratings for Rs 72.5 crore in bank facilities, citing coverage by India Ratings. However, CRISIL migrated the ratings to 'Issuer Not Cooperating' (BB/Stable) prior to withdrawal because the company failed to provide requisite information and No Default Statements for three months. This development coincides with a weak Q1 FY27 performance, where the company reported a net loss of Rs 45.19 crore, and the receipt of five USFDA observations at its Pashamylaram facility. While the company maintains that borrowing arrangements are unaffected, the lack of cooperation with a major rating agency is a red flag for transparency.
Confidence: HIGH
What changedCRISIL ratings for specific bank facilities were withdrawn at the company's request after being downgraded to 'Non-Cooperative' status due to a lack of management interaction.
Why it mattersThe 'Issuer Not Cooperating' tag often signals potential internal governance or transparency issues. Combined with recent USFDA observations and a quarterly loss, it suggests increased operational and regulatory risk for the pharmaceutical player.
Rated Facilities: Rs 72.5 CrFacilities vs TTM Revenue: 3.53%Q1 FY27 Net Loss: Rs 45.19 CrUSFDA Observations: 5Previous Long-term Rating: CRISIL AA-/Positive
📅 Short termThe stock may face pressure due to the negative optics of a 'Non-Cooperative' rating migration and the disclosure of USFDA observations.
📈 Long termThe long-term outlook depends on the successful integration of recent acquisitions (NJ Bio, Sapala) and the resolution of USFDA regulatory hurdles at manufacturing sites.
⚠ Risk flags
- Non-cooperation with credit rating agency
- USFDA Form 483 observations
- Recent shift from profit to loss in Q1 FY27
- High export exposure (85%)
Key Highlights
CRISIL migrated long-term ratings from 'AA-/Positive' to 'BB/Stable (Issuer Not Cooperating)' before final withdrawal.
The withdrawal affects bank loan facilities totaling Rs 72.5 crore, representing ~3.5% of TTM revenue.
Company reported a consolidated net loss of Rs 45.19 crore in Q1 FY27 versus a profit of Rs 46.40 crore in the previous year's quarter.
USFDA issued 5 observations in Form 483 following an inspection of the Pashamylaram, Hyderabad facility.
CRISIL noted the company failed to provide No Default Statements (NDS) for the last three consecutive months.
👀 What to Watch
Investors should closely monitor the company's response to the 5 USFDA observations and its upcoming quarterly results to see if the Q1 FY27 loss was a one-off. Verification of the 'India Ratings' report is advised to confirm the credit outlook from the alternative agency.
38.7% Revenue Drop in Pharma CDMO; Cohance Guides for H2 FY27 Recovery
Cohance Lifesciences reported that Q1 FY27 was its lowest-ever quarter, with Pharma CDMO revenue declining 38.7% YoY due to shipment phasing. Management expects a return to year-on-year growth starting in H2 FY27, supported by restocking orders and the delivery of a customized ADC payload order in Q2 FY27. The company is integrating its nucleic acid business (Sapala) with a defined path to full ownership by FY30. Additionally, CFO Himanshu Agarwal is set to depart on September 13, 2026, with a succession process underway.
Confidence: HIGH
What changedThe company has transitioned through its guided 'lowest quarter' and formalized the integration timeline for its high-growth nucleic acid platform (Sapala).
Why it mattersThe recovery in H2 FY27 is critical to maintaining the company's 20-25% long-term growth target and validating the synergy benefits of the recent merger and acquisitions.
Pharma CDMO Revenue Growth (YoY): -38.7%New API Filings (FY27 Target): 7CFO Departure Date: 13 September 2026TTM Revenue: Rs 2051 CrFull Ownership Target (Sapala): FY30
📅 Short termThe stock may remain range-bound as the market waits for Q2 FY27 results to confirm the start of the guided operational recovery.
📈 Long termStructural growth is tied to the integration of ADCs and Oligonucleotides, which are expected to reach low 20s percentage of CDMO revenue by end of FY26.
⚠ Risk flags
- Management transition risk with the CFO exit
- Execution risk in meeting H2 FY27 recovery guidance
- High export exposure (85%) to currency fluctuations
Key Highlights
Pharma CDMO revenue declined by 38.7% YoY in Q1 FY27 due to customer shipment phasing.
Management expects a return to year-on-year growth from the second half (H2) of FY27.
Company plans to file 7 new products in the API+ segment during FY27, following 9 filings in the previous year.
A clear path to 100% ownership of the Sapala (nucleic acid) business has been established for completion by FY30.
CFO Himanshu Agarwal will step down effective September 13, 2026, after supporting the merger integration.
👀 What to Watch
Monitor the execution of the ADC payload order delivery in Q2 FY27 and the realization of restocking orders in H2 FY27 to confirm the guided recovery trajectory.
5 USFDA Observations Issued for Cohance Lifesciences' Pashamylaram Facility
Cohance Lifesciences completed a 10-day USFDA inspection at its Pashamylaram, Hyderabad facility on August 5, 2026. The inspection resulted in a Form 483 with 5 observations, though the company confirmed that none relate to data integrity issues. This facility is a key asset for a company with TTM revenue of ₹2,051 Cr and a market cap of ₹13,299 Cr. The company is currently preparing a comprehensive response and corrective actions (CAPAs) for submission within the required timeline.
Confidence: HIGH
What changedThe USFDA has concluded its inspection of the Pashamylaram facility, moving from an active audit status to the post-inspection observation phase.
Why it mattersRegulatory compliance is critical for Cohance's export-heavy business model (85% export exposure). While 5 observations are not uncommon, any escalation to 'Official Action Indicated' (OAI) could stall new product approvals and impact the targeted 20-25% growth rate.
Number of observations: 5Inspection duration: 10 daysTTM Revenue: ₹2051 CrMarket Cap: ₹13299 CrFY26 New Product Target: 5 products
📅 Short termThe stock may face minor pressure or volatility until the nature of the 5 observations is clarified and the USFDA accepts the company's response.
📈 Long termIf the observations are procedural and resolved via CAPAs, the long-term growth strategy involving ADCs and Oligos remains intact. However, repeated regulatory hurdles could de-rate the current high P/E of 73.7.
⚠ Risk flags
- Regulatory escalation if CAPAs are insufficient
- Potential delay in US DMF approvals
- History of OAI status at other facilities (Nacharam) impacting production
Key Highlights
Inspection conducted over 10 days from July 27, 2026, to August 5, 2026
Received Form 483 containing 5 observations at the conclusion of the audit
Zero observations related to data integrity, reducing the risk of severe regulatory escalation
Facility located at Pashamylaram, Hyderabad (FEI No. 1000623515)
Company targeting 10 DMF filings in US and Europe in FY26, making compliance critical
👀 What to Watch
Watch for the USFDA's final classification of the inspection (NAI, VAI, or OAI). Investors should monitor if these observations delay the commercialization of the 5 new products planned for FY26.
23.1% Revenue Decline in Q1 FY27; Cohance Reports Adjusted Net Loss of ₹43 Cr
Cohance Lifesciences reported a weak Q1 FY27 with consolidated revenue falling 23.1% YoY to ₹422.3 Cr, attributed to shipment phasing in Pharma CDMO and lower formulation sales. Adjusted EBITDA margins collapsed to 2.2% from 24.4% YoY, severely impacted by negative operating leverage and a ₹32.8 Cr EBITDA loss from the NJ Bio subsidiary. Despite the consolidated loss, the company remains net-cash positive with ₹458.9 Cr on the books and generated ₹106.3 Cr in free cash flow. Management has guided for a recovery weighted towards H2 FY27, supported by a 2.5x revenue growth in the Sapala (nucleic-acid) business.
Confidence: HIGH
What changedThe company has transitioned into a consolidated entity including NJ Bio and Sapala, leading to temporary margin pressure and a reported loss due to integration costs and shipment phasing.
Why it mattersThe results reflect the volatility of the CDMO business model and the immediate financial drag of newly acquired high-growth platforms (NJ Bio) before they reach scale.
Revenue (Q1 FY27): ₹422.3 CrAdjusted EBITDA Margin: 2.2%Sapala Revenue Growth: 2.5xNJ Bio EBITDA Loss: ₹32.8 CrCash on Books: ₹458.9 CrCapex vs TTM Revenue: ~2.9%
📅 Short termThe stock may face pressure due to the sharp margin contraction and reported loss, although management had previously guided for a weak Q1.
📈 Long termThe structural shift towards ADCs and Oligonucleotides through NJ Bio and Sapala remains the core growth driver, with FY27 expected to be a transition year before full scale-up in FY28.
⚠ Risk flags
- Operating losses at NJ Bio subsidiary
- High shipment phasing volatility in CDMO
- Regulatory normalization risks at Nacharam facility
Key Highlights
Consolidated revenue declined 23.1% YoY to ₹422.3 Cr, with API+ segment down 10.4% and Specialty Chemicals down 34.7%.
Adjusted EBITDA fell 93.2% YoY to ₹9.2 Cr, with margins contracting by 2,220 bps to 2.2%.
NJ Bio subsidiary consolidation contributed a significant EBITDA loss of ₹32.8 Cr during the quarter.
Sapala Organics revenue grew 2.5x YoY, while Niche technology share reached 15.1% of total revenue.
Free cash flow generation remained positive at ₹106.3 Cr despite the reported loss, with ₹59.8 Cr deployed in capex.
👀 What to Watch
Investors should monitor the guided recovery in H2 FY27, specifically looking for the normalization of the Nacharam formulation facility and the conversion of the 10-molecule Phase III CDMO pipeline into commercial orders.
23.1% Revenue Decline in Q1 FY27; Cohance Reports Weakest Quarter, Guides for H2 Recovery
Cohance Lifesciences reported a weak Q1 FY27 with consolidated revenue falling 23.1% YoY to ₹422.3 Cr, attributed to a lower CDMO contribution (38%) and order phasing. Adjusted EBITDA plummeted to ₹9.2 Cr as the company faced negative operating leverage and losses in its NJ Bio subsidiary. Management has labeled this the 'lowest quarter ever' and expects a return to YoY growth in the second half of FY27, supported by secured orders and a late-stage pipeline. The company maintains a healthy net cash position of ₹251.2 Cr despite the operational slowdown.
Confidence: HIGH
What changedThe company has hit a guided financial trough in Q1 FY27, transitioning through the integration of Sapala and NJ Bio while repositioning its Agrochemicals portfolio.
Why it mattersThis quarter represents the 'bottom' according to management; the business's ability to bounce back in H2 will validate the merger synergy and the shift toward high-margin ADC and Oligo segments.
Q1 FY27 Revenue: ₹422.3 CrYoY Revenue Growth: -23.1%Adjusted EBITDA: ₹9.2 CrNet Cash: ₹251.2 CrCapex vs TTM Revenue: ~2.9%CDMO Revenue Share: 38%
📅 Short termExpect short-term pressure on the stock price due to the sharp EBITDA contraction and revenue decline, though management's pre-emptive guidance may mitigate some shock.
📈 Long termThe structural focus on ADCs and integrated nucleic acids (Sapala) remains the long-term value driver, provided the H2 FY27 recovery materializes as guided.
⚠ Risk flags
- Negative operating leverage
- Losses in NJ Bio subsidiary
- Lumpy nature of CDMO order book
- Ongoing regulatory remediation at Nacharam facility
Key Highlights
Consolidated revenue from operations declined 23.1% YoY to ₹422.3 Cr.
Adjusted EBITDA stood at ₹9.2 Cr, reflecting significant margin compression from negative operating leverage.
CDMO business contribution dropped to 38% of total revenue, down from historical levels due to order phasing.
Capital expenditure of ₹59.8 Cr was deployed during the quarter for capacity and capability building.
Net cash position remains robust at ₹251.2 Cr as of June 30, 2026.
👀 What to Watch
Watch for the execution of two commercialized molecules scheduled for delivery in Q2 and Q3, which are critical to meeting the management's H2 recovery guidance.
₹45.19 Cr Net Loss: Cohance Reports 23% Revenue Decline in Q1 FY27; Sapala Merger Roadmap Set
Cohance Lifesciences reported a weak Q1 FY27 with consolidated revenue from operations falling 23.1% YoY to ₹422.26 cr. The company swung to a consolidated net loss of ₹45.19 cr, compared to a profit of ₹46.40 cr in the same quarter last year. Performance was weighed down by a ₹16.51 cr exceptional item related to a customer settlement and higher operational expenses relative to lower sales. Additionally, the company announced a phased acquisition of the remaining 49% stake in Sapala Organics to reach 100% ownership by FY30.
Confidence: HIGH
What changedThe company transitioned from a profitable quarter to a significant net loss and formalized the timeline to fully integrate Sapala Organics into its nucleic acid business platform.
Why it mattersThe results highlight ongoing operational headwinds and regulatory impacts (OAI status mentioned in context), while the Sapala reorganization is critical for the company's long-term strategy in high-growth Oligo and ADC segments.
Consolidated Revenue (Q1 FY27): ₹422.26 crConsolidated Net Loss (Q1 FY27): ₹45.19 crExceptional Item (Settlement): ₹16.51 crRevenue vs TTM Revenue: ~20.6%Sapala Stake to be acquired by FY27: 21%
📅 Short termThe stock may face downward pressure due to the unexpected net loss and significant revenue contraction compared to the previous year.
📈 Long termThe structural integration of Sapala and NJ Bio positions the company for high-growth niche technologies, but FY27 is clearly a transition year with recovery expected only from FY28.
⚠ Risk flags
- Regulatory OAI status at Nacharam facility
- Significant revenue contraction
- Exceptional settlement costs
- Execution risk in multi-year subsidiary integration
Key Highlights
Consolidated revenue from operations declined 23.1% YoY to ₹422.26 cr from ₹549.31 cr.
Reported a consolidated net loss of ₹45.19 cr against a profit of ₹46.40 cr in Q1 FY26.
Exceptional item of ₹16.51 cr recognized as a claim payable to a customer under a settlement agreement.
Phased acquisition of Sapala Organics: 21% stake to be acquired after FY27 results and 28% after FY30 results.
Standalone revenue fell 25.6% YoY to ₹359.89 cr, reflecting broader pressure in the core CDMO business.
👀 What to Watch
Investors should monitor the 'corrective and preventive action programme' at the Nacharam facility and the progress of the 5 new product launches planned for FY27 to gauge recovery timing.
Cohance Lifesciences CFO Himanshu Agarwal Resigns to Pursue External Opportunity
Mr. Himanshu Agarwal has resigned from his dual roles as Whole-time Director and Chief Financial Officer of Cohance Lifesciences Limited, effective September 13, 2026. The resignation is intended to allow him to pursue a professional opportunity outside the organization. The company, formerly known as Suven Pharmaceuticals, has approximately three months to manage the transition before his final working day. Agarwal has confirmed there are no material reasons for his departure other than career advancement.
Key Highlights
Himanshu Agarwal to step down as CFO and Whole-time Director effective September 13, 2026.
Resignation announced on June 17, 2026, providing a notice period of nearly three months for a smooth handover.
Reason for departure cited as a new professional opportunity aligning with long-term career aspirations.
The outgoing CFO confirmed no other material reasons for resignation exist.
Company must now identify and appoint a successor for the Key Managerial Personnel (KMP) role.
👀 What to Watch
Investors should monitor the company's progress in appointing a new CFO to ensure continuity in financial governance and strategic execution. The three-month notice period mitigates immediate operational risk, but the quality of the successor will be critical.
Cohance Lifesciences Shareholders Approve Umang Vohra as Chairman & CEO and New ESOP 2026 Plan
Cohance Lifesciences Limited (formerly Suven Pharmaceuticals) has successfully passed five key resolutions via postal ballot with requisite majorities. Shareholders approved the appointment of Umang Vohra as Chairman and Group CEO, alongside a new Employee Stock Option Plan (ESOP) 2026. While all resolutions passed, there was notable institutional resistance regarding executive remuneration and large ESOP grants, with over 40% of institutional votes cast against these specific items. The promoter group, holding 219.93 million shares, voted 100% in favor of all resolutions.
Key Highlights
Umang Vohra confirmed as Chairman and Group CEO with 99.62% total votes in favor.
ESOP 2026 plan approved with 96.57% support, including extension to unlisted subsidiaries.
Remuneration for Umang Vohra exceeding statutory limits passed with 88.57% majority, despite 40.61% institutional dissent.
Resolution to grant options exceeding 1% of issued capital in a year passed with 88.16% support, facing 42.04% institutional opposition.
Total voting turnout was high at 89.42%, representing 342.09 million shares out of 382.57 million total shares.
👀 What to Watch
Investors should welcome the leadership stability provided by Umang Vohra's formal appointment but should monitor the high institutional dissent regarding executive pay and potential equity dilution from the new ESOP scheme.
Cohance Lifesciences FY26 Revenue Declines 13% to ₹22.68B; Recovery Projected for H2 FY27
Cohance Lifesciences reported a challenging FY26 with revenue falling 13% YoY to INR 22.68 billion, primarily due to inventory destocking in the CDMO segment and operational disruptions at the Nacharam facility. Adjusted EBITDA stood at INR 4.77 billion with a 21% margin, though gross margins remained resilient at 70.8%. Management, led by new CEO Umang Vohra, expects Q1 FY27 to be the low point for the company, with a visible recovery in growth and margins starting from the second half of FY27. The company plans to increase capex to INR 3 billion in FY27 to bolster its ADC and oligonucleotide platforms.
Key Highlights
FY26 Revenue stood at INR 22.68 billion, a 13% YoY decline; Adjusted EBITDA margin at 21%.
Pharma CDMO segment impacted by INR 260 crore due to destocking in two large commercial molecules.
API+ business revenue fell 8% to INR 10.88 billion, including a INR 610 million impact from Nacharam site disruptions.
Phase 3 pipeline expanded to 10 programs, with significant progress in Antibody-Drug Conjugates (ADCs).
Planned capex of INR 3 billion for FY27, up from INR 2.15 billion in FY26.
👀 What to Watch
Investors should closely monitor the recovery of the two major CDMO molecules and the stabilization of the Nacharam site in H1 FY27. The long-term outlook remains tied to the successful scale-up of the high-margin ADC and oligonucleotide pipelines under new leadership.
Cohance Lifesciences Appoints Umang Vohra as Chairman & Group CEO; Proposes New ESOP 2026 Plan
Cohance Lifesciences (formerly Suven Pharmaceuticals) has initiated a postal ballot to appoint Umang Vohra as Chairman and Group CEO for a five-year term starting May 2026. The company is also seeking approval for the 'Employee Stock Option Plan 2026', which includes provisions to grant options exceeding 1% of the issued capital in a single financial year. Furthermore, shareholders are being asked to approve executive remuneration for Mr. Vohra that may exceed standard statutory limits under Section 197 of the Companies Act. These strategic moves signal a major leadership transition and a focus on long-term employee incentive alignment.
Key Highlights
Appointment of Umang Vohra as Chairman (eff. May 1, 2026) and Group CEO (eff. May 20, 2026) until April 2031.
Introduction of 'Employee Stock Option Plan 2026' covering both the company and its unlisted subsidiaries.
Proposal to grant stock options equal to or exceeding 1% of issued capital in a single financial year.
Seeking shareholder approval for remuneration exceeding limits prescribed under Section 197 of the Companies Act, 2013.
Remote e-voting period scheduled from May 15, 2026, to June 13, 2026, with results by June 15, 2026.
👀 What to Watch
Investors should view the appointment of a high-profile leader like Umang Vohra as a positive indicator for future growth and strategic direction. However, keep an eye on the potential equity dilution resulting from the new ESOP 2026 plan.
Cohance Lifesciences FY26 Revenue Falls 13% to ₹22.7 Bn; PAT Down 65% Amid Transition Year
Cohance Lifesciences reported a challenging FY26 with consolidated revenue declining 13% YoY to INR 22.68 billion and adjusted PAT falling 65.4% to INR 1.84 billion. The performance was severely impacted by inventory de-stocking in major CDMO products and a INR 610 million disruption at the Nacharam formulation plant. While Q4 revenue fell 26.3% YoY, the company maintains a robust pipeline with 10 Phase III molecules and expects a recovery starting from 2HFY27. Management has guided that Q1FY27 will likely be the low point before growth returns.
Key Highlights
FY26 Revenue declined 13% YoY to INR 22.68 Bn, while Adjusted EBITDA margins contracted to 21% from 33.7% in FY25.
Pharma CDMO segment faced headwinds from de-stocking in two large commercial products, though the pipeline expanded to 10 Phase III molecules.
The API+ segment was impacted by a INR 610 Mn disruption at the Nacharam plant, which is now back to operational levels.
Free Cash Flow remained positive at INR 1.73 Bn with a healthy cash balance of INR 3.22 Bn as of March 31, 2026.
Management expects FY27 to be a growth year, though Q1FY27 is anticipated to be the low point for both revenue and EBITDA.
👀 What to Watch
Investors should brace for a weak Q1FY27 and monitor the execution of the Phase III pipeline for a recovery in the second half of the year. The significant margin contraction and profit decline suggest caution until volume recovery and better capacity utilization are visible.
Cohance Lifesciences FY26 Net Profit Drops 69% to ₹150.12 Cr; Revenue Falls 13%
Cohance Lifesciences (formerly Suven Pharmaceuticals) reported a weak set of results for the fiscal year ended March 31, 2026. Consolidated revenue declined by 13% to ₹2,268.55 crore, while net profit witnessed a sharp 69% contraction to ₹150.12 crore compared to the previous year. The fourth quarter was particularly stressed, with net profit plunging to ₹8.31 crore from ₹117.15 crore in the year-ago period. The company also updated its Key Managerial Personnel for materiality disclosures, naming Umang Vohra as Chairman.
Key Highlights
Consolidated annual revenue decreased 13% YoY to ₹2,268.55 crore from ₹2,608.50 crore.
Annual net profit plummeted 69% to ₹150.12 crore compared to ₹484.24 crore in FY25.
Q4 FY26 consolidated net profit stood at a mere ₹8.31 crore vs ₹117.15 crore in Q4 FY25.
Full-year Basic EPS fell significantly to ₹4.69 from ₹12.79 in the previous fiscal year.
The company reported exceptional items totaling ₹29.47 crore for the full year.
👀 What to Watch
Investors should be concerned by the significant margin erosion and sharp decline in profitability. It is recommended to review the investor presentation to identify if these results are due to one-time merger-related costs or a fundamental shift in business dynamics.
Cohance Lifesciences Appoints Industry Veteran Umang Vohra as Chairman and Group CEO
Cohance Lifesciences (formerly Suven Pharmaceuticals) has detailed the profile of its new Chairman and Group CEO, Mr. Umang Vohra. Mr. Vohra brings over 30 years of leadership experience, including a decade-long tenure as MD and Global CEO of Cipla Limited. His previous experience also includes 14 years at Dr. Reddy’s Laboratories as CFO and head of North America generics, signaling a high-caliber leadership transition for the company.
Key Highlights
Mr. Umang Vohra appointed as Chairman and Group CEO with 30+ years of industry experience.
Previously served as Managing Director and Global CEO of Cipla Limited for 10 years.
Spent 14 years at Dr. Reddy’s Laboratories in strategic roles including CFO and Head of North America generics.
Educational background includes an MBA from TAPMI and a B.E. in Computer Science.
👀 What to Watch
Investors should view this leadership appointment as a strong positive, given Mr. Vohra's proven track record in scaling large-cap Indian pharma companies. Monitor for new strategic initiatives or expansion plans under his guidance.
Umang Vohra Appointed as Executive Chairman & Group CEO of Cohance Lifesciences
Cohance Lifesciences has appointed Umang Vohra, the former CEO and MD of Cipla, as its new Executive Chairman and Group CEO. Mr. Vohra will take over the Chairman role on May 1, 2026, and the CEO role on May 20, 2026, succeeding Vivek Sharma. The outgoing Chairman will remain as an advisor for 9 months to ensure a smooth leadership transition. This appointment is a strategic move to scale Cohance's CDMO platform, which currently utilizes over 400 R&D scientists and specialized chemistry capabilities.
Key Highlights
Umang Vohra to assume Executive Chairman role on May 1, 2026, and Group CEO on May 20, 2026
Vohra previously led Cipla Limited as CEO and MD for a decade, driving its global transformation
Outgoing Chairman Vivek Sharma to provide transition support as an Advisor for the next 9 months
Cohance operates a specialized CDMO platform with over 400 R&D scientists focused on complex APIs and ADCs
👀 What to Watch
This is a high-profile leadership upgrade that signals aggressive growth ambitions for the CDMO platform. Investors should maintain a positive outlook as Vohra's proven track record at Cipla could significantly enhance Cohance's global market position.
